{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:14:29Z","timestamp":1793042069432,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","croh-online.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.critrevonc.2017.08.003","type":"journal-article","created":{"date-parts":[[2017,8,25]],"date-time":"2017-08-25T10:47:16Z","timestamp":1503658036000},"page":"79-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":243,"special_numbering":"C","title":["Mechanisms and risk factors of thrombosis in cancer"],"prefix":"10.1016","volume":"118","author":[{"given":"Anna","family":"Falanga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"Milesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Vignoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.critrevonc.2017.08.003_bib0005","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1182\/blood-2008-02-142422","article-title":"High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)","volume":"112","author":"Ay","year":"2008","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.critrevonc.2017.08.003_bib0010","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.21.7752","article-title":"D-dimer and prothrombin fragment 1+2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study","volume":"27","author":"Ay","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.critrevonc.2017.08.003_bib0015","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1182\/blood-2010-02-270116","article-title":"Prediction of venous thromboembolism in cancer patients","volume":"116","author":"Ay","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2017.08.003_bib0020","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"Blom","year":"2005","journal-title":"JAMA"},{"issue":"40","key":"10.1016\/j.critrevonc.2017.08.003_bib0025","doi-asserted-by":"crossref","first-page":"42733","DOI":"10.18632\/oncotarget.5811","article-title":"Identification of a novel platelet antagonist that binds to CLEC-2 and suppresses podoplanin-induced platelet aggregation and cancer metastasis","volume":"6","author":"Chang","year":"2015","journal-title":"Oncotarget"},{"issue":"Suppl 2","key":"10.1016\/j.critrevonc.2017.08.003_bib0030","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/S0049-3848(07)70130-5","article-title":"Thrombophilia and risk of venous thrombosis in patients with cancer","volume":"120","author":"Decousus","year":"2007","journal-title":"Thromb. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2017.08.003_bib0035","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1538-7836.2006.02301.x","article-title":"Microvesicle-associated tissue factor and Trousseau's syndrome","volume":"5","author":"Del Conde","year":"2007","journal-title":"J. Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.critrevonc.2017.08.003_bib0040","doi-asserted-by":"crossref","first-page":"e22946","DOI":"10.4161\/onci.22946","article-title":"Neutrophil extracellular traps: a new link to cancer-associated thrombosis and potential implications for tumor progression","volume":"2","author":"Demers","year":"2013","journal-title":"Oncoimmunology"},{"issue":"5","key":"10.1016\/j.critrevonc.2017.08.003_bib0045","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1111\/jth.12192","article-title":"Validation of the Ottawa prognostic score for the prediction of recurrent venous thromboembolism in patients with cancer-associated thrombosis","volume":"11","author":"den Exter","year":"2013","journal-title":"J. Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.critrevonc.2017.08.003_bib0050","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2141.1993.tb03218.x","article-title":"Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery","volume":"85","author":"Falanga","year":"1993","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.critrevonc.2017.08.003_bib0055","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1182\/blood.V86.3.1072.1072","article-title":"Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid","volume":"86","author":"Falanga","year":"1995","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2017.08.003_bib0060","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/blood.V92.1.143.413k18_143_151","article-title":"Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells","volume":"92","author":"Falanga","year":"1998","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2017.08.003_bib0065","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/ajh.10073","article-title":"Effect of all-trans-retinoic acid on the hypercoagulable state of patients with breast cancer","volume":"70","author":"Falanga","year":"2002","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2017.08.003_bib0070","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1055\/s-2005-863812","article-title":"Thrombophilia in cancer","volume":"31","author":"Falanga","year":"2005","journal-title":"Semin. Thromb. Hemost."},{"issue":"29","key":"10.1016\/j.critrevonc.2017.08.003_bib0075","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1200\/JCO.2009.22.8197","article-title":"Venous thromboembolism in the hematologic malignancies","volume":"27","author":"Falanga","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2017.08.003_bib0080","doi-asserted-by":"crossref","first-page":"115","DOI":"10.5482\/ha-1170","article-title":"Epidemiology, risk and outcomes of venous thromboembolism in cancer","volume":"32","author":"Falanga","year":"2012","journal-title":"Hamostaseologie"},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2017.08.003_bib0085","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1016\/S0049-3848(12)70033-6","article-title":"Microparticles in tumor progression","volume":"129","author":"Falanga","year":"2012","journal-title":"Thromb. Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2017.08.003_bib0090","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/jth.12075","article-title":"Coagulation and cancer: biological and clinical aspects","volume":"11","author":"Falanga","year":"2013","journal-title":"J. Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.critrevonc.2017.08.003_bib0095","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/MOH.0000000000000072","article-title":"The coagulopathy of cancer","volume":"21","author":"Falanga","year":"2014","journal-title":"Curr. Opin. Hematol."},{"issue":"7","key":"10.1016\/j.critrevonc.2017.08.003_bib0100","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1055\/s-0035-1564040","article-title":"Cancer tissue procoagulant mechanisms and the hypercoagulable state of patients with cancer","volume":"41","author":"Falanga","year":"2015","journal-title":"Semin. Thromb. Hemost."},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2017.08.003_bib0105","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S0049-3848(15)50432-5","article-title":"The mechanisms of cancer-associated thrombosis","volume":"135","author":"Falanga","year":"2015","journal-title":"Thromb. Res."},{"issue":"52","key":"10.1016\/j.critrevonc.2017.08.003_bib0110","doi-asserted-by":"crossref","first-page":"43565","DOI":"10.1074\/jbc.M112.401760","article-title":"Cancer cells induced to express mesenchymal phenotype release exosome-like extracellular vesicles carrying tissue factor","volume":"287","author":"Garnier","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.critrevonc.2017.08.003_bib0115","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1002\/cncr.21496","article-title":"Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study","volume":"104","author":"Khorana","year":"2005","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2017.08.003_bib0120","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"issue":"Suppl. 2","key":"10.1016\/j.critrevonc.2017.08.003_bib0125","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S0049-3848(14)50006-0","article-title":"Risk stratification strategies for cancer-associated thrombosis: an update","volume":"133","author":"Khorana","year":"2014","journal-title":"Thromb. Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2017.08.003_bib0130","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0959-8049(02)00596-8","article-title":"Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor","volume":"39","author":"Kim","year":"2003","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2017.08.003_bib0135","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.leukres.2010.11.008","article-title":"The expression of annexin II and its role in the fibrinolytic activity in acute promyelocytic leukemia","volume":"35","author":"Liu","year":"2011","journal-title":"Leuk. Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2017.08.003_bib0140","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1161\/CIRCULATIONAHA.111.051920","article-title":"Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism","volume":"126","author":"Louzada","year":"2012","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.critrevonc.2017.08.003_bib0145","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1200\/JCO.2014.59.7351","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014","volume":"33","author":"Lyman","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 2","key":"10.1016\/j.critrevonc.2017.08.003_bib0150","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0049-3848(14)50001-1","article-title":"Oncogenes and the coagulation system--forces that modulate dormant and aggressive states in cancer","volume":"133","author":"Magnus","year":"2014","journal-title":"Thromb. Res."},{"issue":"9","key":"10.1016\/j.critrevonc.2017.08.003_bib0155","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1073\/pnas.1314118111","article-title":"Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations","volume":"111","author":"Magnus","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.critrevonc.2017.08.003_bib0160","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/annonc\/mdr524","article-title":"Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the \u2018SENDO experience\u2019","volume":"23","author":"Mandala","year":"2012","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2017.08.003_bib0165","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00401-006-0063-y","article-title":"Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression","volume":"111","author":"Mishima","year":"2006","journal-title":"Acta Neuropathol."},{"issue":"25","key":"10.1016\/j.critrevonc.2017.08.003_bib0170","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1200\/JCO.2011.35.5669","article-title":"High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis","volume":"29","author":"Moore","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2017.08.003_bib0175","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/S0049-3848(16)30097-4","article-title":"Heparanase procoagulant activity in cancer progression","volume":"140","author":"Nadir","year":"2016","journal-title":"Thromb. Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2017.08.003_bib0180","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.critrevonc.2017.08.003_bib0185","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1182\/blood-2004-06-2272","article-title":"Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells","volume":"105","author":"Palumbo","year":"2005","journal-title":"Blood"},{"issue":"5B","key":"10.1016\/j.critrevonc.2017.08.003_bib0190","first-page":"2997","article-title":"The role of podoplanin in tumor progression and metastasis","volume":"28","author":"Raica","year":"2008","journal-title":"Anticancer Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2017.08.003_bib0195","doi-asserted-by":"crossref","first-page":"V215","DOI":"10.1016\/S0049-3848(01)00285-7","article-title":"Molecular basis for the relationship between thrombosis and cancer","volume":"102","author":"Rickles","year":"2001","journal-title":"Thromb. Res."},{"issue":"Suppl. 2","key":"10.1016\/j.critrevonc.2017.08.003_bib0200","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/S0049-3848(14)50025-4","article-title":"Mechanistic explanation for platelet contribution to cancer metastasis","volume":"133","author":"Stegner","year":"2014","journal-title":"Thromb. Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2017.08.003_bib0205","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.thromres.2007.12.023","article-title":"Tissue factor activity is increased in a combined platelet and microparticle sample from cancer patients","volume":"122","author":"Tilley","year":"2008","journal-title":"Thromb. Res."},{"issue":"10","key":"10.1016\/j.critrevonc.2017.08.003_bib0210","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","article-title":"Epidemiology of cancer-associated venous thrombosis","volume":"122","author":"Timp","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2017.08.003_bib0215","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1160\/TH07-10-0602","article-title":"Platelet-derived microparticles and coagulation activation in breast cancer patients","volume":"100","author":"Toth","year":"2008","journal-title":"Thromb. Haemost."},{"issue":"7","key":"10.1016\/j.critrevonc.2017.08.003_bib0220","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3324\/haematol.13774","article-title":"Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia","volume":"94","author":"Trappenburg","year":"2009","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.critrevonc.2017.08.003_bib0225","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11739-012-0784-y","article-title":"A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score","volume":"7","author":"Verso","year":"2012","journal-title":"Intern. Emerg. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2017.08.003_bib0230","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1055\/s-0037-1613190","article-title":"Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation","volume":"88","author":"Weitz","year":"2002","journal-title":"Thromb. Haemost."},{"issue":"22","key":"10.1016\/j.critrevonc.2017.08.003_bib0235","doi-asserted-by":"crossref","first-page":"6830","DOI":"10.1158\/1078-0432.CCR-09-0371","article-title":"Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy","volume":"15","author":"Zwicker","year":"2009","journal-title":"Clin. Cancer Res."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842817303141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842817303141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T08:04:13Z","timestamp":1602835453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842817303141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":47,"alternative-id":["S1040842817303141"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2017.08.003","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms and risk factors of thrombosis in cancer","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2017.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}